Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Diabetes

Free Subscription Articles published in Ann Intern Med Retrieve available abstracts of 78 articles: HTML format

Single Articles

October 2025
1. SHAHID M, Gandhi GY
   In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA(1c) vs. placebo at 40 wk.
   Ann Intern Med. 2025;178:JC114.
   PubMed     Abstract available
   
   
   
2. TANNER M
   In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA(1c) at 52 wk.
   Ann Intern Med. 2025;178:JC113.
   PubMed     Abstract available
   
   
   
3. LAU D, Padwal R
   In T2D and hypertension, the lower-sodium DASH4D diet reduced SBP more than a higher-sodium comparison diet at 5 wk.
   Ann Intern Med. 2025;178:JC115.
   PubMed     Abstract available
   
   
   September 2025
4. WEITZ HH, Merli GJ
   Annals Consult Guys - Diabetes Issues in Ambulatory Surgery.
   Ann Intern Med. 2025;178:e2504052CG.
   PubMed    
   
   
   
5. ADES M, Anand SS
   In symptomatic peripheral artery disease with T2D, semaglutide increased maximum walking distance at 1 y.
   Ann Intern Med. 2025;178:JC100.
   PubMed     Abstract available
   
   
   August 2025
6. RUIZ-CANELA M, Corella D, Martinez-Gonzalez MA, Babio N, et al
   Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes : A Secondary Analysis of a Randomized Controlled Trial.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
   PubMed     Abstract available
   
   
   
7. 
   Summary for Patients: Comparison of an Energy-Reduced Mediterranean Diet and Physical Activity Versus an Ad Libitum Mediterranean Diet in the Prevention of Type 2 Diabetes.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-00388.
   PubMed    
   
   
   
8. HERRING SJ, Tripicchio GL
   Reducing Diabetes Risk Through the Mediterranean Diet.
   Ann Intern Med. 2025 Aug 26. doi: 10.7326/ANNALS-25-02748.
   PubMed    
   
   
   
9. NADGIR U, Ali SR, Gogate J, Shaw W, et al
   Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.
   Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
   PubMed     Abstract available
   
   
   
10. 
    Summary for Patients: Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes.
    Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-24-04017.
    PubMed    
    
    
    
11. CENTOR RM, Billings LK
    Annals On Call - Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control Is Inadequate With Dulaglutide.
    Ann Intern Med. 2025 Aug 5:e2503404OC. doi: 10.7326/ANNALS-25-03404.
    PubMed    
    
    
    
12. BRADY RP, Shah AS
    Expanding the Treatment Vault: Canagliflozin in Youth With Type 2 Diabetes.
    Ann Intern Med. 2025 Aug 5. doi: 10.7326/ANNALS-25-02805.
    PubMed    
    
    
    
13. CENTOR RM, Kip K, Saeed A
    Web Exclusive. Annals On Call - Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes.
    Ann Intern Med. 2025;178:e2503594OC.
    PubMed    
    
    
    
14. LAU D, Senior P
    In insulin-treated T2D, automated insulin delivery reduced HbA(1c) without increasing hypoglycemic events vs. usual care at 13 wk.
    Ann Intern Med. 2025;178:JC95.
    PubMed     Abstract available
    
    
    July 2025
15. PLASCENCIA-VILLA G, Xu R, Perry G
    Potential Effects of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Diabetes and High Risk for Dementia.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02362.
    PubMed    
    
    
    
16. WU Z, Sheng C, Guo Z, Zheng Y, et al
    Association of Weekend Warrior and Other Physical Activity Patterns With Mortality Among Adults With Diabetes : A Cohort Study.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-00640.
    PubMed     Abstract available
    
    
    
17. SIGAL RJ, Boule NG
    Physical Activity in Type 2 Diabetes: Could One or Two Weekly Sessions Be Enough?
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-25-02522.
    PubMed    
    
    
    
18. INOUE K, Saliba D, Gotanda H, Moin T, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Incidence of Dementia Among Older Adults With Type 2 Diabetes : A Target Trial Emulation.
    Ann Intern Med. 2025 Jul 22. doi: 10.7326/ANNALS-24-02648.
    PubMed     Abstract available
    
    
    
19. NOH Y, Yin H, Yu OHY, Bitton A, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.
    Ann Intern Med. 2025 Jul 15. doi: 10.7326/ANNALS-24-03420.
    PubMed     Abstract available
    
    
    
20. BANDI SSS, Montori VM
    In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02173.
    PubMed     Abstract available
    
    
    
21. SHAHID M, Gandhi GY
    In patients with diabetes and previous MI, high-dose multivitamins and minerals did not reduce CV events.
    Ann Intern Med. 2025 Jul 1. doi: 10.7326/ANNALS-25-02174.
    PubMed     Abstract available
    
    
    June 2025
22. SAEED A, Mulukutla SR, Thoma F, Lemon L, et al
    Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed     Abstract available
    
    
    
23. 
    Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
    Ann Intern Med. 2025 Jun 17. doi: 10.7326/ANNALS-24-00775.
    PubMed    
    
    
    
24. CENTOR RM, Moiz A
    Annals On Call - Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in the Absence of Diabetes.
    Ann Intern Med. 2025 Jun 3:e2502205OC. doi: 10.7326/ANNALS-25-02205.
    PubMed    
    
    
    
25. THAKKAR A, Newby LK
    In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo.
    Ann Intern Med. 2025 Jun 3. doi: 10.7326/ANNALS-25-01791.
    PubMed     Abstract available
    
    
    May 2025
26. QASEEM A, Basch P, Campos K, MacDonald ST, et al
    Quality Indicators for Diabetes in Adults: A Review of Performance Measures by the American College of Physicians.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-24-03770.
    PubMed     Abstract available
    
    
    
27. LAU D
    In adults with overweight or obesity and without diabetes, GLP-1 RAs increase weight loss vs. placebo.
    Ann Intern Med. 2025 May 6. doi: 10.7326/ANNALS-25-01325.
    PubMed     Abstract available
    
    
    
28. OSTROMINSKI JW, Ortega-Montiel J, Tesfaye H, Alix C, et al
    Trends in Utilization of Glucose- and Weight-Lowering Medications After Tirzepatide Approval in the United States : A Population-Based Cohort Study.
    Ann Intern Med. 2025;178:620-633.
    PubMed     Abstract available
    
    
    April 2025
29. MAKAM AN, Bailey L, Anderson N, Bellitti K, et al
    Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program.
    Ann Intern Med. 2025 Apr 22. doi: 10.7326/ANNALS-24-01449.
    PubMed     Abstract available
    
    
    
30. BILLINGS LK, Winne L, Sharma P, Gomez-Valderas E, et al
    Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed     Abstract available
    
    
    
31. 
    Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
    Ann Intern Med. 2025 Apr 4. doi: 10.7326/ANNALS-24-03849.
    PubMed    
    
    
    
32. SHADBOLT C, Elkin J, Schilling C, Hua X, et al
    National Trends in Glucagon-Like Peptide-1 Receptor Agonist Use in Adults Without Diabetes, 2018 to 2022.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-24-02878.
    PubMed    
    
    
    
33. CENTOR RM, Maciejewski ML, Sloan C
    Annals On Call - Health Expenditures of Patients With Diabetes After Bariatric Surgery.
    Ann Intern Med. 2025;178:e2501511OC.
    PubMed    
    
    
    
34. AMAN M, Jeevananthan A, Martinez-Cruz M, Namasingh N, et al
    Endocrinology: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00990.
    PubMed     Abstract available
    
    
    March 2025
35. OSERAN AS, Aggarwal R, Figueroa J, Joynt Maddox KE, et al
    Prevalence of Chronic Medical Conditions Among Medicare Advantage and Traditional Medicare Beneficiaries.
    Ann Intern Med. 2025;178:327-335.
    PubMed     Abstract available
    
    
    February 2025
36. TANG H, Lu Y, Donahoo WT, Westen SC, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression in Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2025 Feb 25. doi: 10.7326/ANNALS-24-01347.
    PubMed     Abstract available
    
    
    January 2025
37. MACIEJEWSKI ML, Zepel L, Smith VA, Arterburn DE, et al
    Health Expenditures of Patients With Diabetes After Bariatric Surgery: Comparing Gastric Bypass and Sleeve Gastrectomy.
    Ann Intern Med. 2025 Jan 28. doi: 10.7326/ANNALS-24-00480.
    PubMed     Abstract available
    
    
    
38. 
    Annals Video Summary - Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7:e2403525VS. doi: 10.7326/ANNALS-24-03525.
    PubMed    
    
    
    
39. 
    Summary for Patients: Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed    
    
    
    
40. MOIZ A, Filion KB, Toutounchi H, Tsoukas MA, et al
    Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
    Ann Intern Med. 2025 Jan 7. doi: 10.7326/ANNALS-24-01590.
    PubMed     Abstract available
    
    
    
41. LARIOS F, Gionfriddo MR, Montori VM
    In T1D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) but increased severe hypoglycemia at 26 wk.
    Ann Intern Med. 2025;178:JC11.
    PubMed     Abstract available
    
    
    
42. LARIOS F, Gionfriddo MR, Montori VM
    In insulin-naive T2D, weekly efsitora was noninferior to daily degludec for reducing HbA(1c) at 52 wk.
    Ann Intern Med. 2025;178:JC10.
    PubMed     Abstract available
    
    
    December 2024
43. VASSILOPOULOS S, Mylonakis E
    After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
    Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
    PubMed     Abstract available
    
    
    
44. GIANCHANDANI R, Wei M, Demidowich A
    Management of Hyperglycemia in Hospitalized Patients.
    Ann Intern Med. 2024;177:ITC177-ITC192.
    PubMed     Abstract available
    
    
    November 2024
45. ZHU D, Herrington WG
    In adults with BMI >/=27 kg/m(2) and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA(1c) level.
    Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02457.
    PubMed     Abstract available
    
    
    
46. MAHER M, Dinneen S
    In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use.
    Ann Intern Med. 2024;177:JC124.
    PubMed     Abstract available
    
    
    
47. ZHU D, Herrington WG
    In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.
    Ann Intern Med. 2024;177:JC123.
    PubMed     Abstract available
    
    
    October 2024
48. FITCH KV, Zanni MV, Manne-Goehler J, Diggs MR, et al
    Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial.
    Ann Intern Med. 2024 Oct 8. doi: 10.7326/ANNALS-24-00944.
    PubMed     Abstract available
    
    
    
49. HONG B, Bea S, Ko HY, Kim WJ, et al
    Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia : A Population-Based Cohort Study.
    Ann Intern Med. 2024;177:1319-1329.
    PubMed     Abstract available
    
    
    September 2024
50. COLLISTER D, Pannu N
    In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y.
    Ann Intern Med. 2024;177:JC98.
    PubMed     Abstract available
    
    
    
51. YEO YH, Rezaie A, Hsieh TY, Hu X, et al
    Shifting Trends in the Indication of Glucagon-like Peptide-1 Receptor Agonist Prescriptions: A Nationwide Analysis.
    Ann Intern Med. 2024;177:1289-1291.
    PubMed    
    
    
    August 2024
52. CHAITOFF A, Bendicksen L, Feldman WB, Zheutlin AR, et al
    Estimating New Eligibility and Maximum Costs of Expanded Medicare Coverage of Semaglutide for Cardiovascular Risk Prevention.
    Ann Intern Med. 2024 Aug 27. doi: 10.7326/ANNALS-24-00308.
    PubMed    
    
    
    
53. KANJEE Z, Brown FM, Taxin ZH, Smetana GW, et al
    How Would You Treat This Inpatient With Type 2 Diabetes Mellitus? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Aug 13. doi: 10.7326/ANNALS-24-01100.
    PubMed     Abstract available
    
    
    July 2024
54. WANG W, Volkow ND, Berger NA, Davis PB, et al
    Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
    Ann Intern Med. 2024 Jul 30. doi: 10.7326/M23-2718.
    PubMed     Abstract available
    
    
    
55. TANG H, Lu Y, Donahoo WT, Shao H, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes : A Target Trial Emulation Study.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/M24-0329.
    PubMed     Abstract available
    
    
    
56. 
    Summary for Patients: Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Jul 16. doi: 10.7326/P24-0004.
    PubMed    
    
    
    
57. CENTOR RM, Crandall CJ
    Annals On Call - ACP Recommendation: Pharmacologic Treatment of Type 2 Diabetes.
    Ann Intern Med. 2024;177:e2401521OC.
    PubMed    
    
    
    
58. TANNER M
    In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality.
    Ann Intern Med. 2024;177:JC83.
    PubMed     Abstract available
    
    
    
59. CHIU YH, Huybrechts KF, Patorno E, Yland JJ, et al
    Metformin Use in the First Trimester of Pregnancy and Risk for Nonlive Birth and Congenital Malformations: Emulating a Target Trial Using Real-World Data.
    Ann Intern Med. 2024;177:862-870.
    PubMed     Abstract available
    
    
    June 2024
60. CRAWFORD AL, Laiteerapong N
    Type 2 Diabetes.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/AITC202406180.
    PubMed     Abstract available
    
    
    
61. SMETANA GW, Romeo GR, Rosas SE, Burns RB, et al
    How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
    Ann Intern Med. 2024 Jun 11. doi: 10.7326/M24-0764.
    PubMed     Abstract available
    
    
    May 2024
62. LAINE C, Moyer DV, Qaseem A
    Newer Pharmacologic Treatments for Type 2 Diabetes.
    Ann Intern Med. 2024 May 28. doi: 10.7326/ANNALS-24-00698.
    PubMed    
    
    
    
63. O'BRIEN C, Dinneen SF
    In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0028.
    PubMed     Abstract available
    
    
    
64. BATES ER
    In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo.
    Ann Intern Med. 2024 May 7. doi: 10.7326/J24-0026.
    PubMed     Abstract available
    
    
    
65. MARUTHUR NM, Pilla SJ, White K, Wu B, et al
    Effect of Isocaloric, Time-Restricted Eating on Body Weight in Adults With Obesity : A Randomized Controlled Trial.
    Ann Intern Med. 2024;177:549-558.
    PubMed     Abstract available
    
    
    April 2024
66. YEN FS, Hwu CM, Liu JS, Wu YL, et al
    Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Dialysis and Cardiovascular Disease in Patients With Stage 5 Chronic Kidney Disease.
    Ann Intern Med. 2024 Apr 30. doi: 10.7326/M23-1874.
    PubMed     Abstract available
    
    
    
67. DRAKE T, Landsteiner A, Langsetmo L, MacDonald R, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1490.
    PubMed     Abstract available
    
    
    
68. SCHOUSBOE JT, Landsteiner A, Drake T, Sultan S, et al
    Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-1492.
    PubMed     Abstract available
    
    
    
69. QASEEM A, Obley AJ, Shamliyan T, Hicks LA, et al
    Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M23-2788.
    PubMed     Abstract available
    
    
    
70. SYED FZ
    Pharmacologic Treatments in Adults With Type 2 Diabetes: Cost-Effectiveness and Comorbidity Considerations.
    Ann Intern Med. 2024 Apr 19. doi: 10.7326/M24-0861.
    PubMed    
    
    
    
71. 
    Annals Video Summary - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes.
    Ann Intern Med. 2024 Apr 19:eM231554. doi: 10.7326/M23-1554.
    PubMed    
    
    
    
72. 
    Visual Guideline - Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Visual Clinical Guideline From the American College of Physicians.
    Ann Intern Med. 2024 Apr 19:eM240803. doi: 10.7326/M24-0803.
    PubMed     Abstract available
    
    
    
73. KELSEY M, Newby LK
    In higher-risk, statin-intolerant adults with diabetes, bempedoic acid reduced MACE at a median 3 y.
    Ann Intern Med. 2024 Apr 2. doi: 10.7326/J24-0016.
    PubMed     Abstract available
    
    
    
74. HWANG JH, Hsu CY
    In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type.
    Ann Intern Med. 2024;177:JC40.
    PubMed     Abstract available
    
    
    
75. EGAN AM
    In T2DM, periconceptional, noninsulin, second-line antidiabetes medications were not linked to major congenital malformations vs. insulin.
    Ann Intern Med. 2024;177:JC47.
    PubMed     Abstract available
    
    
    March 2024
76. GARABEDIAN LF, Zhang F, Costa R, Argetsinger S, et al
    Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
    Ann Intern Med. 2024 Mar 26. doi: 10.7326/M23-1965.
    PubMed     Abstract available
    
    
    
77. KOUTROUMPAKIS E, Deswal A
    In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo.
    Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0008.
    PubMed     Abstract available
    
    
    
78. PERSELL SD, Petito LC, Lee JY, Meeker D, et al
    Reducing Care Overuse in Older Patients Using Professional Norms and Accountability : A Cluster Randomized Controlled Trial.
    Ann Intern Med. 2024;177:324-334.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.